High frequency of BRAF mutations in nevi
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [226]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
The Regulation of Normal Melanocyte Proliferation
Halaban, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130103.x · Cited by 179
Research works printed but not linked: 2
- Armstrong, B.K. & English, D.R. in Cancer Epidemiology and Prevention (Oxford University Press, New York, 1996).
- Elder, D.E. & Murphy, G.F. in Atlas of Tumor Pathology: Melanocytic Tumors of the Skin 5–101 (Armed Forces Insititute of Pathology, Washington, DC, 1991).
Cited by
Items 401–500 of 1,001
Targeting Mitochondrial Metabolism by Inhibiting Autophagy in BRAF-Driven Cancers
Strohecker, A. M., & White, E. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0196 · Cited by 84
Confirmation of a BRAF mutation‐associated gene expression signature in melanoma
Johansson, P., Pavey, S., & Hayward, N. (2007) · Pigment Cell Research · doi:10.1111/j.1600-0749.2007.00375.x · Cited by 84
“The discovery of BRAF mutations in melanomas (Davies et al., 2002) and naevi (Pollock et al., 2003) has provided one of the most important advances in understanding pigment cell neoplasia.”
BackgroundSelf-citationNRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
Tschandl, P., Berghoff, A. S., Preusser, M., Burgstaller-Muehlbacher, S., Pehamberger, H., Okamoto, I., & Kittler, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069639 · Cited by 91
“It is also known that BRAF mutations occur at a similar frequency in nevi and in primary and metastatic melanomas [9,19–22].”
BackgroundSenescence As an Anticancer Mechanism
Hornsby, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3101 · Cited by 90
PBISe, a novel selenium-containing drug for the treatment of malignant melanoma
Madhunapantula, S. V., Desai, D. H., Sharma, A. K., Huh, S. J., Amin, S., & Robertson, G. P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2267 · Cited by 83
Dessars, B., Raeve, L. E. D., Morandini, R., Lefort, A., Housni, H. E., Ghanem, G., den Eynde, B. J. V., Ma, W., Roseeuw, D. I., Vassart, G., et al. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.203 · Cited by 92
“According to the literature, the frequency of NRAS mutations is higher in medium CMNs than in small CMNs and acquired nevi (Pollock et al., 2003; Papp et al., 2005; IchiiNakato et al., 2006).”
BackgroundLiang, S., Sharma, A. K., Peng, H., Robertson, G. P., & Dong, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4233 · Cited by 82
“B-Raf mutation is implicated in constitutive activation and hyperactivation of downstream proteins in the signaling cascade that promotesmelanoma adhesion, migration, and proliferation (1, 4, 6, 7).”
BackgroundMarín, Y. E., Namkoong, J., Cohen-Solal, K., Shin, S., Martino, J. J., Oka, M., & Chen, S. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.10.012 · Cited by 90
Frequency of UV-Inducible NRAS Mutations in Melanomas of Patients With Germline CDKN2A Mutations
Eskandarpour, M., Hashemi, J., Kanter, L., Ringborg, U., Platz, A., & Hansson, J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.11.790 · Cited by 83
Targeting drivers of melanoma with synthetic small molecules and phytochemicals
Strickland, L. R., Pal, H. C., Elmets, C. A., & Afaq, F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.016 · Cited by 91
“Of note, BRAF mutations are also found in many benign nevi [41].”
BackgroundBandyopadhyay, D., Curry, J. L., Lin, Q., Richards, H. W., Chen, D., Hornsby, P. J., Timchenko, N. A., & Medrano, E. E. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00308.x · Cited by 82
“Five-µm thick formalin-fixed paraffin-embedded melanocytic nevi samples were derived from the tissue archives of the Section of Dermatopathology, Department of Pathology, Baylor College of Medicine.”
BackgroundInfluentialFeng, Y.-Z., Shiozawa, T., Miyamoto, T., Kashima, H., Kurai, M., 鈴木, 昭., & Konishi, I. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2670 · Cited by 81
A Role for ATF2 in Regulating MITF and Melanoma Development
Shah, M., Bhoumik, A., Goel, V., Dewing, A., Breitwieser, W., Kluger, H., Krajewski, S., Krajewska, M., DeHart, J., Lau, E., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001258 · Cited by 81
“Previous studies indicate the presence of mutant BRAF in melanocytic lesions, as well as its effect on pigment gene expression [6,50,51].”
BackgroundElder, D. E. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03450.x · Cited by 82
Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway
Lin, M.-T., Bi, H. S., Yan, Y., Huang, W., Zhang, G., Zhang, G., Tang, S., Liu, Y., Zhang, L., Ma, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15584 · Cited by 80
Mirmohammadsadegh, A., Mota, R., Gustrau, A., Hassan, M., Nambiar, S., Marini, A., Bojar, H., Tannapfel, A., & Hengge, U. R. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700870 · Cited by 80
“However, this mutation was also observed in 82% of nevi, suggesting that the RAS/RAF/MAPK pathway is a critical step in the initiation of melanocyte neoplasias but that by itself seems insufficient to cause melanomagenesis (Pollock et al., 2003).”
BackgroundTargeting Intracellular Signaling Pathways as a Novel Strategy in Melanoma Therapeutics
Smalley, K. S. M., & Herlyn, M. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1339.005 · Cited by 88
Kelleher, F. C., & McArthur, G. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824ba4df · Cited by 87
Takata, M., Lin, J., Takayanagi, S., Suzuki, T., Ansai, S., Kimura, T., Cerroni, L., & Saida, T. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07924.x · Cited by 81
Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors
Haferkamp, S., Scurr, L. L., Becker, T. M., Frausto, M., Kefford, R. F., & Rizos, H. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.5 · Cited by 92
“The activation of the RAS signaling cascade is not sufficient to induce melanoma, however, as cells in 80% of benign nevi express oncogenic B-RAF or N-RAS (Dong et al., 2003; Pollock et al., 2003; Kumar et al., 2004; Poynter et al., 2006; Bauer et al., 2007).”
BackgroundLymphatic Mapping Establishes the Role of BRAF Gene Mutation in Papillary Thyroid Carcinoma
Kim, J., Giuliano, A. E., Turner, R. R., Gaffney, R., Umetani, N., Kitago, M., Elashoff, D. A., & Hoon, D. S. �. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224751.80858.13 · Cited by 79
Therapeutic strategies for inhibiting oncogenic BRAF signaling
Halilovic, E., & Solit, D. B. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.014 · Cited by 82
Recent Advances in Melanoma Biology
Perlis, C., & Herlyn, M. (2004) · The Oncologist · doi:10.1634/theoncologist.9-2-182 · Cited by 93
“B-raf mutations have been detected in nonmalignant nevi [ 30 ], suggesting that B-Raf is insufficient for transformation.”
BackgroundBrouwer, N. J., Verdijk, R. M., Heegaard, S., Marinkovic, M., Esmaeli, B., & Jager, M. J. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100971 · Cited by 85
“The abundance of BRAF mutations in conjunctival nevi parallels that of nevi of the skin, where a study reported these in 82% (Pollock et al., 2003).”
BackgroundAkslen, L. A., Puntervoll, H. E., Bachmann, I. M., Straume, O., Vuhahula, E. A. M., Kumar, R., & Molven, A. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e3282f32517 · Cited by 85
Yu, H., McDaid, R., Lee, J., Possik, P. A., Li, L., Kumar, S. M., Elder, D. E., Belle, P. A. V., Gimotty, P. A., Guerra, M., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081057 · Cited by 94
“Eighty percent of nevi harbor BRAF mutations, with the most frequent mutation being a valine-to-glutamic acid substitution at position 600 (V600E).(1) BRAF has highly-elevated kinase activity and confers constitutive activation of the MAPK pathway.”
BackgroundThe relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence
Haferkamp, S., Tran, S. L., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2009) · Aging · doi:10.18632/aging.100051 · Cited by 77
Panagopoulos, I., Mertens, F., Isaksson, M., & Mandahl, N. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.04.008 · Cited by 77
“Recently, a high incidence of activating mutations in the BRAF gene has been reported in melanoma cell lines, melanoma short term cultures, primary and metastatic melanomas, and nevi [9–12].”
BackgroundDesign and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors
Ramurthy, S., Subramanian, S., Aikawa, M., Amiri, P., Costales, A., Dove, J., Fong, S. K., Jansen, J. M., Levine, B. H., Ma, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801050k · Cited by 77
Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients
Daniotti, M., Vallacchi, V., Rivoltini, L., Patuzzo, R., Santinami, M., Arienti, F., Cutolo, G., Pierotti, M. A., Parmiani, G., & Rodolfo, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22598 · Cited by 76
Ikenoue, T., Hikiba, Y., Kanai, F., Aragaki, J., Tanaka, Y., Imamura, J., Imamura, T., Ohta, M., Ijichi, H., Tateishi, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3591 · Cited by 77
Tsai, K. Y., & Tsao, H. (2004) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30037 · Cited by 87
“…dominant activating mutations in the BRAF proto-oncogene in a majority of both melanoma samples, melanoma cell lines, and nevi [Davies et al., 2002; Pollock et al., 2003] has served as valuable confirmation of the involve- ment of the RAS pathway in human melanoma tumorigenesis and…”
BackgroundGenetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Griewank, K., Scolyer, R. A., Thompson, J. F., Flaherty, K. T., Schadendorf, D., & Murali, R. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt435 · Cited by 84
“BRAF mutations appear to be an early event in tumorigenesis because they are also found in the majority of common acquired nevi (34).”
BackgroundGenetic alterations in melanocytic tumors
Takata, M., & Saida, T. (2006) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2006.05.002 · Cited by 85
“Shortly after the compelling discovery of BRAF mutations in melanoma [7], BRAF mutations were also found to be common in melanocytic nevi, including both acquired and congenital nevi, as well as dysplastic nevi [45].”
BackgroundClonality and Evolutionary History of Rhabdomyosarcoma
Chen, L., Shern, J. F., Wei, J. S., Yohe, M. E., Song, Y., Hurd, L., Liao, H., Catchpoole, D. R., Skapek, S. X., Barr, F. G., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005075 · Cited by 83
B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis
Boisvert-Adamo, K., & Aplin, A. E. (2006) · Oncogene · doi:10.1038/sj.onc.1209493 · Cited by 83
“Although B-RAF activation alone is not sufficient to transform a melanocyte, as B-RAF mutations are also found in melanocytic nevi (Pollock et al., 2003), the constitutive MEK–ERK1/2 signaling resulting from the B-RAFV600E mutation has been shown to regulate G1 cell cycle events in primary human…”
BackgroundTargeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease
Vultur, A., Villanueva, J., & Herlyn, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0174 · Cited by 81
“insufficient for tumorigenesis and that additional factors are needed for cancer progression (13).”
BackgroundDNA Mutations May Not Be the Cause of Cancer
Adjiri, A. (2017) · Oncology and Therapy · doi:10.1007/s40487-017-0047-1 · Cited by 79
“a modification at the DNA level as causal in cancer, becomes evident in the fact that mutations in BRAF and NRAS, originally qualified as drivers, could not fully explain melanoma oncogenesis, as these same mutations have been found at similar rates in benign nevi [38, 39].”
BackgroundThe protective role of DOT1L in UV-induced melanomagenesis
Zhu, B., Chen, S., Wang, H., Yin, C., Han, C., Peng, C., Liu, Z., Wan, L., Zhang, X., Zhang, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02687-7 · Cited by 76
Self-citationUBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling
Dikshit, A., Jin, Y. J., Degan, S., Hwang, J., Foster, M. W., Li, C., & Zhang, J. Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1040 · Cited by 80
Lack of Association between BRAF Mutation and MAPK ERK Activation in Melanocytic Nevi
Uribe, P., Andrade, L., & González, S. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700011 · Cited by 81
“BRAF activating mutations have been found in a high proportion of melanomas (56–66%), AN (52–80%), and common nevi (CN) (73–82%) (Davies et al., 2002; Pollock et al., 2003; Uribe et al., 2003).”
BackgroundEpigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma
Arab, K., Smith, L. T., Gast, A., Weichenhan, D., Huang, P.-H., Claus, R., Hielscher, T., Espinosa, A. V., Ringel, M. D., Morris, Q., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr138 · Cited by 79
The role of mitogen‐ and stress‐activated protein kinase pathways in melanoma
Lopez‐Bergami, P. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00908.x · Cited by 83
“These and other evidences strongly suggest that ERK activation is a critical step in nevus formation and melanoma initiation (Dhomen et al., 2009; Hoeflich et al., 2006; Omholt et al., 2003; Pollock et al., 2003).”
BackgroundChen, S.-H., Gong, X., Zhang, Y., Horn, R. D. V., Yin, T., Huber, L., Burke, T., Manro, J. R., Iversen, P. W., Wu, W., et al. (2017) · Oncogene · doi:10.1038/onc.2017.384 · Cited by 77
Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro
Cook, A. L., Smith, A. G., Smit, D. J., Leonard, J. H., & Sturm, R. A. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.04.019 · Cited by 73
The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function
Wan, L., Chen, M., Cao, J., Dai, X., Yin, Q., Zhang, J., Song, S.-J., Lu, Y., Liu, J., Inuzuka, H., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0647 · Cited by 74
The multifaceted anti-cancer effects of BRAF-inhibitors
Croce, L., Coperchini, F., Magri, F., Chiovato, L., & Rotondi, M. (2019) · Oncotarget · doi:10.18632/oncotarget.27304 · Cited by 83
“Of note common precancerous lesions, such as melanocytic nevi, are characterized by a strikingly high frequency of BRAF-mutations, suggesting that mutational activation of the RAS/RAF/MAPK pathway is a critical step in the initiation of melanocytic neoplasia even if its presence alone is likely not sufficient for mela…”
BackgroundMelanoma: Epidemiology, Diagnosis, Treatment, and Outcomes
Tuong, W., Cheng, L. S., & Armstrong, A. W. (2011) · Dermatologic Clinics · doi:10.1016/j.det.2011.08.006 · Cited by 92
“Germline mutations in 1 or both of these gene products are associated with familial melanoma, and have been ascertained in 25% to 50% of familial melanoma kindreds worldwide and in approximately 10% of patients with multiple primary melanoma.(26) Identifying individual contributions of p16 and ARF to melanoma tumorige…”
BackgroundNFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma
Flockhart, R. J., Armstrong, J. L., Reynolds, N. J., & Lovat, P. E. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605277 · Cited by 79
“Although BRAF is also mutated in up to 80% of benign melanocytic naevi (Pollock et al, 2003), the proportion of naevi Received 24 April 2009; revised 29 June 2009; accepted 27 July 2009; published online 1 September 2009 *Correspondence: Professor NJ Reynolds; E-mail: n.j.reynolds@ncl.ac.uk 2 Joint…”
BackgroundA genome-wide scan for naevus count: linkage to CDKN2A and to other chromosome regions
Zhu, G., Montgomery, G. W., James, M. R., Trent, J. M., Hayward, N. K., Martin, N. G., & Duffy, D. L. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201729 · Cited by 74
Self-citationActivating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi
Möller, I., Murali, R., Müller, H., Wiesner, T., Jackett, L. A., Scholz, S. L., Cosgarea, I., van de Nes, J. A. P., Sucker, A., Hillen, U., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.201 · Cited by 75
The Spitzoid Lesion: The Importance of Atypical Variants and Risk Assessment
Barnhill, R. L. (2006) · American Journal of Dermatopathology · doi:10.1097/01.dad.0000188868.19869.3b · Cited by 72
Bedogni, B., O’Neill, M. S., Welford, S. M., Bouley, D. M., Giaccia, A. J., Denko, N. C., & Powell, M. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3327 · Cited by 74
“The same activating mutation has been identified in benign melanocytic proliferations, which has led to the speculation that BRaf activation, although not sufficient for melanocyte transformation, may also be an early event in the process (23).”
BackgroundTargeting the duality of cancer
Arbiser, J. L., Bonner, M. Y., & Gilbert, L. C. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0026-x · Cited by 75
Lang, J., & MacKie, R. M. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23833.x · Cited by 75
How I manage pulmonary Langerhans cell histiocytosis
Lorillon, G., & Tazi, A. (2017) · European Respiratory Review · doi:10.1183/16000617.0070-2017 · Cited by 71
Polubothu, S., McGuire, N., Al-Olabi, L., Baird, W., Bulstrode, N., Chalker, J., Josifova, D. J., Lomas, D., O’Hara, J., Ong, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18106 · Cited by 77
Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome
Weeraratna, A. T., Becker, D., Carr, K. M., Duray, P. H., Rosenblatt, K. P., Yang, S. W., Chen, Y., Bittner, M. L., Strausberg, R. L., Riggins, G. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207337 · Cited by 82
Self-citationCharacterization of Ser338 Phosphorylation for Raf-1 Activation
Zang, M., Gong, J., Luo, L., Zhou, J., Xiang, X., Huang, W., Huang, Q., Luo, X., Olbrot, M., Peng, Y., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802855200 · Cited by 80
BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations
Piris, A., Mihm, M. C., & Hoang, M. P. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.10.015 · Cited by 73
“In addition, Spitz nevi have not been reported to harbor BRAF mutation [23], whereas common acquired nevi frequently have BRAF mutation [24].”
BackgroundDifferential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
Marsh Durban, V., Deuker, M. M., Bosenberg, M. W., Phillips, W., & McMahon, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69619 · Cited by 71
“Indeed, the vast majority of benign nevi (common moles) express BRAF V600E , but these initiated lesions rarely progress to melanoma (6).”
Genetic and environmental melanoma models in fish
Patton, E. E., Mitchell, D. L., & Nairn, R. S. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00693.x · Cited by 70
“Further analysis of nevi (benign accumulations of melanocytes, commonly known as moles) revealed that the majority of nevi also had BRAF mutations, suggesting that BRAF mutations alone are not sufficient to promote melanoma (Pollock et al., 2003).”
Bourcier, C., Griseri, P., Grépin, R., Bertolotto, C., Mazure, N., & Pagès, G. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00506.2010 · Cited by 71
“The fact that 80% of benign nevi present with the V600E mutation (39) and that expression of the B-RAF V600E mutation alone failed to fully transform melanocytes favors this point of view (9).”
BackgroundBurger, M. C., Ronellenfitsch, M. W., Lorenz, N. I., Wagner, M., Voß, M., Capper, D., Tzaridis, T., Herrlinger, U., Steinbach, J. P., Stoffels, G., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6013 · Cited by 70
KLF9-dependent ROS regulate melanoma progression in stage-specific manner
Bagati, A., Moparthy, S., Fink, E. E., Bianchi, A., Yun, D. H., Kolesnikova, M., Udartseva, O. O., Wolff, D. W., Roll, M. V., Lipchick, B. C., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0689-6 · Cited by 76
Yeh, I., BUSAM, K. J., McCalmont, T. H., LeBoit, P. E., Pissaloux, D., Alberti, L., de la Fouchardière, A., & Bastian, B. C. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001235 · Cited by 70
β‐Catenin in the Melanocyte Lineage
Larue, L., Kumasaka, M. Y., & Goding, C. R. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00050.x · Cited by 88
Massi, D., Simi, L., Sensi, E., Baroni, G., Xue, G., Scatena, C., Caldarella, A., Pinzani, P., Fontanini, G., Carobbio, A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.137 · Cited by 71
Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling
Vergara, I. A., Mintoff, C., Sandhu, S. K., McIntosh, L., Young, R. J., Wong, S. Q., Colebatch, A. J., Cameron, D., Lai-Kwon, J. E., Wolfe, R. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21576-8 · Cited by 71
Self-citationUnusual variants of malignant melanoma
Barnhill, R. L., & Gupta, K. (2009) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.015 · Cited by 78
Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma
Sommerer, F., Vieth, M. W., Markwarth, A., Röhrich, K., Vomschloß, S., May, A., Ell, C., Stolte, M., Hengge, U. R., Wittekind, C., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207189 · Cited by 69
Badal, B., Solovyov, A., Cecilia, S. D., Chan, J. M., Chang, L., Iqbal, R., Aydin, I. T., Rajan, G. S., Chen, C., Abbate, F., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92102 · Cited by 77
Activating mutations in the MAP‐kinase pathway define non‐ossifying fibroma of bone
Baumhoer, D., Kovac, M. B., Sperveslage, J., Ameline, B., Strobl, A., Krause, A., Trautmann, M., Wardelmann, E., Nathrath, M., Höller, S., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5216 · Cited by 74
“BRAF and NRAS mutations, for example, commonly occur as early clonal events in melanocytic nevi whereas activating mutations in the FGFR3 gene, that belong to the most prevalent mutations in bladder cancer, occur in >50% of seborrheic keratoses and epidermal nevi [11-16].”
BackgroundThe Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
Vanni, I., Tanda, E. T., Spagnolo, F., Andreotti, V., Bruno, W., & Ghiorzo, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00113 · Cited by 72
Lade‐Keller, J., Rømer, K. M., Guldberg, P., Riber‐Hansen, R., Hansen, L. L., Steiniche, T., Hager, H., & Kristensen, L. S. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.08.003 · Cited by 68
Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune
van den Hurk, K., Niessen, H. E. C., Veeck, J., van den Oord, J. J., Steensel, M. A. M. V., Hausen, A. Z., van Engeland, M., & Winnepenninckx, V. J. L. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.011 · Cited by 79
BRAF mutations in non-Hodgkin's lymphoma
Lee, J. W., Yoo, N. J., Soung, Y. H., Kim, H. S., Park, W. S., Kim, S. Y., Lee, J. H., Park, J. Y., Cho, Y. G., Kim, C. J., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601371 · Cited by 68
“…have been reported within two kinase domains (G-loop and activation segment domains), and the most common mutation is a single substitution, V599E (Brose et al, 2002; Davies et al, 2002; Naoki et al, 2002; Rajagopalan et al, 2002; Yuen et al, 2002; Pollock et al, 2003; Satyamoorthy et al, 2003).”
BackgroundDissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation
Mishra, P. J., Ha, L., Rieker, J., Sviderskaya, E. V., Bennett, D. C., Oberst, M. D., Kelly, K., & Merlino, G. (2010) · Oncogene · doi:10.1038/onc.2009.521 · Cited by 68
“More recently, activating mutations were discovered in BRAF ranging from 44 to 70% of melanomas and nevi, predominantly consisting of V600E (Brose et al., 2002; Davies et al., 2002; Pollock and Meltzer, 2002; Pollock et al., 2003; Bennett, 2008).”
Sclafani, F., Gullo, G., Sheahan, K. D., & Crown, J. P. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.003 · Cited by 76
Wnt signaling potentiates nevogenesis
Pawlikowski, J. S., McBryan, T., van Tuyn, J., Drotar, M. E., Hewitt, R. N., Maier, A. B., King, A., Blyth, K., Wu, H., & Adams, P. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303491110 · Cited by 68
“Mutated N-RAS is also commonly found in benign nevi and melanoma (10, 11).”
BackgroundWenglowsky, S., Ren, L. M., Ahrendt, K. A., Laird, E. R., Aliagas, I., Alicke, B., Buckmelter, A. J., Choo, E. F., Dinkel, V., Feng, B., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200025q · Cited by 68
Genetic progression of metastatic melanoma
Rodolfo, M., Daniotti, M., & Vallacchi, V. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.06.049 · Cited by 79
Wu, J. M., Rosenbaum, E., Begum, S., & Westra, W. H. (2007) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e3181584950 · Cited by 75
“This hot spot was chosen because the reported BRAF-activating mutations in cutaneous nevi and cutaneous melanoma occur almost exclusively at this position.(6,15) PCR primer sequences were designed to amplify a 102-bp fragment of exon 15 (5#GAAGACCTCACAGTAAAAATAGGTGA-3# and 5#-CCA CAAAATGGATCCAGACA-3#).”
BackgroundChloroquine Promotes Apoptosis in Melanoma Cells by Inhibiting BH3 Domain–Mediated PUMA Degradation
Lakhter, A. J., Sahu, R. P., Sun, Y., Kaufmann, W. K., Androphy, E. J., Travers, J. B., & Naidu, S. R. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.56 · Cited by 67
“Oncogenic mutations in BRAF and N-RAS are known to promote melanomagenesis (Dankort et al., 2009; Davies et al., 2002; Pollock et al., 2003).”
BackgroundMutational activation of the RAS‐RAF‐MAPK and the wnt pathway in small intestinal adenocarcinomas
Bläker, H., Helmchen, B., Bönisch, A., Aulmann, S., Penzel, R., Otto, H. F., & Rieker, R. J. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410005847 · Cited by 67
“Mutations inBRAF have recently been described in a large number of melanocytic tumors (16, 17) and in a smaller fraction of other human cancers.”
BackgroundTERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation
Vallarelli, A. F. A., Rachakonda, P. S., André, J., Heidenreich, B., Riffaud, L., Bensussan, A., Kumar, R., & Dumaz, N. (2016) · Oncotarget · doi:10.18632/oncotarget.10634 · Cited by 71
“Mutations in BRAF constitute an early event and occur in over 80% of benign nevi; however, the sustained BRAF or NRAS expression in human melanocytes leads to oncogene-induced senescence [2, 3].”
BackgroundRoss, A. L., Sanchez, M. I., & Grichnik, J. M. (2011) · Dermatology Research and Practice · doi:10.1155/2011/463184 · Cited by 74
“2003 [6] Totala n/a 6 of 7 Histology alone”
BackgroundMethodThe T1796A mutation of the BRAF gene is absent in Spitz nevi
Palmedo, G., Hantschke, M., Rütten, A., Mentzel, T., Hügel, H., Flaig, M. J., Yazdi, A. S., Sander, C. A., & Kutzner, H. (2004) · Journal of Cutaneous Pathology · doi:10.1111/j.0303-6987.2003.00179.x · Cited by 67
“However, this mutation has also been found in a high percentage of benign nevi such as congenital nevi, compound nevi, intradermal nevi, papillomatous nevi, dermal nevi, and dysplastic nevi (Table 1).(2,3) It has previously been noticed that Spitz nevi do not show the T1796A BRAF mutation.”
BackgroundInfluentialZebrafish Models of p53 Functions
Storer, N. Y., & Zon, L. I. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001123 · Cited by 76
“Activating BRAF mutations are also commonly observed in benign nevi (Pollock et al. 2003), or moles, suggesting that mutant BRAF cooperates with other mutations to induce melanoma formation.”
BackgroundKim, I.-J., Park, J.-H., Kang, H. C., Shin, Y., Park, H., Park, H.-R., Ku, J., Lim, S., & Park, J.-G. (2003) · Human Genetics · doi:10.1007/s00439-003-1027-0 · Cited by 66
“A high frequency of BRAF mutations has also been reported in 82% of nevi ( Pollock et al. 2003 ).”
BackgroundGaggioli, C., Robert, G., Bertolotto, C., Bailet, O., Abbe, P., Spadafora, A., Bahadoran, P., Ortonne, J. P., Baron, V. T., Ballotti, R., et al. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700524 · Cited by 66
“BRAF and NRAS mutations appear to be equivalent in the constitutive activation of the MAP kinase signaling pathway and are generally found with mutual exclusion in melanoma (Brose et al., 2002; Davies et al., 2002; Pollock et al., 2003; Garnett and Marais, 2004).”
BackgroundWnt/β-Catenin and MAPK Signaling: Allies and Enemies in Different Battlefields
Guardavaccaro, D., & Clevers, H. C. (2012) · Science Signaling · doi:10.1126/scisignal.2002921 · Cited by 77
Polyclonality of BRAF Mutations in Acquired Melanocytic Nevi
Lin, J., Takata, M., Murata, H., Goto, Y., Kido, K., Ferrone, S., & Saida, T. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp309 · Cited by 69
Hendricks, W. P. D., Zismann, V., Sivaprakasam, K., Legendre, C., Poorman, K. A., Tembe, W., Perdigones, N., Kiefer, J., Liang, W. S., DeLuca, V. J., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007589 · Cited by 72
Self-citationKovalyshyn, I., Braun, R. P., & Marghoob, A. A. (2009) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.2009.00553_1.x · Cited by 66
Basile, K. J., Abel, E. V., & Aplin, A. E. (2012) · Oncogene · doi:10.1038/onc.2011.424 · Cited by 65
“However, the presence of B-RAF mutations in the vast majority of benign nevi indicates that B-RAF V600E is not sufficient for malignant progression (Michaloglou et al. , 2005; Pollock et al. , 2003).”
Mishra, D., Mishra, A., Nand, S., Vamanu, E., & Singh, M. P. (2023) · Diagnostics · doi:10.3390/diagnostics13061142 · Cited by 69
“Although our results suggest that copy number alterations are associated with the changes in gene expression in the five hub genes identified in this study, there are some genes such as CDK4 and MYC, which can be amplified without resulting in increased mRNA levels [43,44].”
ResultTakata, M., Murata, H., & Saida, T. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00645.x · Cited by 78
“Like melanoma, melanocytic nevus frequently harbor activating BRAF mutations (Pollock et al., 2003), which are thought to be an initial step in melanocytic neoplasia; however, the initial growth of melanocytic nevus is followed by stabilization of the size and loss of most proliferative activity.”
BackgroundClinical significance of BRAF mutations in metastatic melanoma
Chang, D. Z., Panageas, K. S., Osman, I., Polsky, D., BUSAM, K. J., & Chapman, P. B. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-46 · Cited by 71
Multiparametric Analysis of Cell-Free DNA in Melanoma Patients
Salvianti, F., Pinzani, P., Verderio, P., Ciniselli, C. M., Massi, D., GIORGI, V. D., Grazzini, M., Pazzagli, M., & Orlando, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049843 · Cited by 68
“BRAF somatic mutations have been reported in 66% of malignant melanomas [13] and are likely to be a crucial step in the initiation of melanocytic neoplasia, as they are found also in melanocytic nevi [14].”
Background
Metadata
- Authors
- Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, P. S.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- The University of Western Australia (AU)
- Corresponding author
- Meltzer, Paul S.
- ORCID
- Venue
- Nature Genetics
- Published
- 2002-11-25
- Volume
- 33
- Issue
- 1
- Pages
- 19-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1565041471
- Cited by
- 1,730
- References
- 4
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 73 · 2020: 58 · 2019: 73 · 2018: 67 · 2017: 87 · 2016: 79 · 2015: 87 · 2014: 84 · 2013: 104 · 2012: 92
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- BRAF mutation, melanocytic nevi, melanoma, melanoma metastasis, RAS/MAPK pathway, carcinogenesis
- MeSH terms
- Cell Transformation, Neoplastic, DNA Mutational Analysis, Gene Frequency, Humans, Melanoma, Nevus, Signal Transduction, Polymerase Chain Reaction, Genetic Predisposition to Disease, Mutation, Missense, Oncogene Proteins v-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.